Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.
- EligibilityCriteria: Inclusion Criteria:  Adult patients aged between 18 and 90 years of age Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40%) Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure  Exclusion Criteria:  Unable to interrupt VKA anticoagulation Point of care International Normalized Ratio (INR) > 1.5 Pregnant patients Acute hospitalization or decompensation within 2 weeks prior to study date Participation in a study involving an investigational drug within 4 weeks prior to study date Inability to lie flat in the supine position Symptomatic hemodynamic instability at rest or during the procedure - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population will include patients who have heart failure with reduced ejection fraction, defined by a left ventricular ejection fraction less than or equal to 40%. - SamplingMethod: Non-Probability Sample